Ivabradine Zentiva

Active Ingredient:: Ivabradine
Origin:: EU

Ivabradine Zentiva (Ivabradine)

Q: What is Ivabradine Zentiva used for?

Ivabradine Zentiva is prescribed to lower heart rate in patients with chronic heart failure (NYHA class II–III) and in those with stable angina pectoris. By reducing the heart rate, it helps alleviate symptoms, improve exercise tolerance, and may decrease the risk of hospitalization related to heart failure.

Q: How does ivabradine work?

Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node, the pacemaker of the heart. This inhibition slows spontaneous depolarisation, leading to a controlled reduction in heart rate while preserving myocardial contractility and blood pressure, making it useful for conditions where heart‑rate control is desired.

Q: What is the usual dose of Ivabradine Zentiva?

The dosage of Ivabradine Zentiva is individualized by the prescribing clinician based on the patient’s clinical condition, heart‑rate target, and tolerance. The prescriber determines the appropriate strength, frequency, and any titration schedule, following local prescribing guidelines.

Q: Is Ivabradine Zentiva safe in pregnancy or breastfeeding?

Safety data for ivabradine during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

Q: How do I order Ivabradine Zentiva from GNH India?

To order Ivabradine Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Q: How does Ivabradine compare with the main alternative drug class?

The primary alternative for heart‑rate reduction in heart failure and angina is the beta‑blocker class. Unlike beta‑blockers, ivabradine lowers heart rate without affecting myocardial contractility or blood pressure, making it useful when beta‑blockers are contraindicated, not tolerated, or when additional rate control is needed.

Q: How should Ivabradine Zentiva be stored and handled?

Ivabradine Zentiva tablets should be stored at ambient temperature below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiry date printed on the label.

Q: How is Ivabradine Zentiva administered?

The medication is taken orally as a tablet, usually with or without food, as directed by the prescriber. Patients are advised to swallow the tablet whole with a glass of water and to follow the dosing schedule set by their healthcare provider.

Q: What are the most serious risks to watch for while taking Ivabradine Zentiva?

The most serious risks include severe bradycardia (heart rate dropping below 50 bpm), symptomatic atrial fibrillation or other arrhythmias, and significant hepatic enzyme elevations. Patients should promptly report dizziness, fainting, palpitations, or any signs of liver dysfunction to their physician.

Q: Who should not use Ivabradine Zentiva?

Ivabradine should be avoided in patients with a resting heart rate below 60 bpm, those with severe hepatic impairment, acute decompensated heart failure, sick sinus syndrome, or in individuals taking strong CYP3A4 inhibitors that could raise drug levels. Contraindications are detailed in the product’s prescribing information.

Ivabradine, the active ingredient in Ivabradine Zentiva, is a If channel inhibitor presented as an oral tablet for oral use. It is indicated for the management of chronic heart failure (NYHA class II–III) and stable angina pectoris, helping to reduce heart rate without compromising myocardial contractility.

GNH India supplies Ivabradine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics across global markets worldwide while adhering to stringent quality and regulatory standards.

Manufacturer / TM Owner

Zentiva, K.S.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine is an If channel inhibitor used in cardiovascular conditions to control heart rate.
Chronic heart failure (NYHA class II–III): Improves symptoms and reduces hospitalization risk by lowering heart rate.
Stable angina pectoris: Decreases frequency of angina attacks through heart‑rate reduction.
Elevated resting heart rate where beta‑blockers are unsuitable: Provides rate control without affecting myocardial contractility.

How It Works

Ivabradine selectively binds to the funny (If) current channels in the sino‑atrial node, inhibiting the inward sodium/potassium mixed current that drives spontaneous depolarisation. This action slows the pacemaker activity, producing a dose‑dependent reduction in heart rate while leaving myocardial contractility, atrioventricular conduction and blood pressure largely unchanged.

Side Effects

Common Side Effects

Bradycardia: heart rate falls below the desired range.
Visual disturbances (phosphenes): transient luminous phenomena.
Headache: mild to moderate intensity.
Dizziness or fatigue: especially during initial therapy.

Serious or Rare Side Effects

Symptomatic severe bradycardia requiring medical intervention.
Atrial fibrillation or other arrhythmias.
Hepatic enzyme elevation indicating possible liver involvement.

Precautions & Warnings

Before starting therapy, evaluate patient suitability and monitor parameters regularly.
Assess heart rate before initiation: ensure resting HR ≥ 60 bpm.
Monitor for symptomatic bradycardia: discontinue if HR < 50 bpm or patient experiences dizziness.
Avoid use in patients with severe hepatic impairment.
Caution in patients with hypotension or concurrent rate‑lowering agents.
Pregnancy and lactation: safety not established; weigh risks and benefits.
Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Ivabradine may interact with several medicines that affect heart rate or its metabolism.

Major Interactions (Avoid)

Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine exposure.
Co‑administration with other bradycardic agents (e.g., beta‑blockers, digoxin) can cause excessive heart‑rate reduction.
Use with verapamil or diltiazem (CYP3A4 inhibitors) increases risk of bradycardia.

Moderate Interactions (Monitor Closely)

CYP3A4 inducers (e.g., rifampicin, carbamazepine) may reduce efficacy.
Drugs that prolong QT interval may increase arrhythmia risk.

Frequently Asked Questions

Ivabradine Zentiva is prescribed to lower heart rate in patients with chronic heart failure (NYHA class II–III) and in those with stable angina pectoris. By reducing the heart rate, it helps alleviate symptoms, improve exercise tolerance, and may decrease the risk of hospitalization related to heart failure.

Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node, the pacemaker of the heart. This inhibition slows spontaneous depolarisation, leading to a controlled reduction in heart rate while preserving myocardial contractility and blood pressure, making it useful for conditions where heart‑rate control is desired.

The dosage of Ivabradine Zentiva is individualized by the prescribing clinician based on the patient’s clinical condition, heart‑rate target, and tolerance. The prescriber determines the appropriate strength, frequency, and any titration schedule, following local prescribing guidelines.

Safety data for ivabradine during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To order Ivabradine Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for heart‑rate reduction in heart failure and angina is the beta‑blocker class. Unlike beta‑blockers, ivabradine lowers heart rate without affecting myocardial contractility or blood pressure, making it useful when beta‑blockers are contraindicated, not tolerated, or when additional rate control is needed.

Ivabradine Zentiva tablets should be stored at ambient temperature below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiry date printed on the label.

The medication is taken orally as a tablet, usually with or without food, as directed by the prescriber. Patients are advised to swallow the tablet whole with a glass of water and to follow the dosing schedule set by their healthcare provider.

The most serious risks include severe bradycardia (heart rate dropping below 50 bpm), symptomatic atrial fibrillation or other arrhythmias, and significant hepatic enzyme elevations. Patients should promptly report dizziness, fainting, palpitations, or any signs of liver dysfunction to their physician.

Ivabradine should be avoided in patients with a resting heart rate below 60 bpm, those with severe hepatic impairment, acute decompensated heart failure, sick sinus syndrome, or in individuals taking strong CYP3A4 inhibitors that could raise drug levels. Contraindications are detailed in the product’s prescribing information.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.